Amphastar P (NASDAQ:AMPH) — Market Cap & Net Worth
Market Cap & Net Worth: Amphastar P (AMPH)
Amphastar P (NASDAQ:AMPH) has a market capitalization of $980.07 Million ($980.07 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9012 globally and #2557 in its home market, demonstrating a 4.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amphastar P's stock price $23.95 by its total outstanding shares 42537944 (42.54 Million). Also see Amphastar P total assets for a full breakdown of the balance sheet.
Amphastar P Market Cap History: 2015 to 2026
Amphastar P's market capitalization history from 2015 to 2026. Data shows growth from $605.31 Million to $1.02 Billion (6.36% CAGR). Also see Amphastar P operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Amphastar P is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #260 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #963 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.05% | #152 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.61 Trillion | 0.08% | #467 of 602 |
Weight: Amphastar P's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amphastar P Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amphastar P's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AMPH stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.58x
Amphastar P's market cap is 1.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.61x
Amphastar P's market cap is 11.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $783.55 Million | $255.16 Million | $10.53 Million | 3.07x | 74.40x |
| 2017 | $818.43 Million | $240.18 Million | $4.51 Million | 3.41x | 181.55x |
| 2018 | $846.51 Million | $294.67 Million | -$5.74 Million | 2.87x | N/A |
| 2019 | $820.56 Million | $322.36 Million | $48.94 Million | 2.55x | 16.77x |
| 2020 | $855.44 Million | $349.85 Million | $1.40 Million | 2.45x | 609.72x |
| 2021 | $990.71 Million | $437.77 Million | $62.12 Million | 2.26x | 15.95x |
| 2022 | $1.19 Billion | $498.99 Million | $91.39 Million | 2.39x | 13.04x |
| 2023 | $2.63 Billion | $644.39 Million | $137.54 Million | 4.08x | 19.13x |
| 2024 | $1.58 Billion | $731.97 Million | $159.52 Million | 2.16x | 9.90x |
| 2025 | $1.14 Billion | $719.89 Million | $98.09 Million | 1.58x | 11.61x |
Competitor Companies of AMPH by Market Capitalization
Companies near Amphastar P in the global market cap rankings as of September 17, 2026. Review AMPH tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Amphastar P by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
Amphastar P Historical Marketcap From 2015 to 2026
Between 2015 and today, Amphastar P's market cap moved from $605.31 Million to $ 1.02 Billion, with a yearly change of 6.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.02 Billion | -10.57% |
| 2025 | $1.14 Billion | -27.88% |
| 2024 | $1.58 Billion | -39.97% |
| 2023 | $2.63 Billion | +120.74% |
| 2022 | $1.19 Billion | +20.31% |
| 2021 | $990.71 Million | +15.81% |
| 2020 | $855.44 Million | +4.25% |
| 2019 | $820.56 Million | -3.07% |
| 2018 | $846.51 Million | +3.43% |
| 2017 | $818.43 Million | +4.45% |
| 2016 | $783.55 Million | +29.44% |
| 2015 | $605.31 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Amphastar P was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $980.07 Million USD |
| MoneyControl | $980.07 Million USD |
| MarketWatch | $980.07 Million USD |
| marketcap.company | $980.07 Million USD |
| Reuters | $980.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more